Allergy Therapeutics (GB:AGY) has released an update.
Allergy Therapeutics plc is advancing towards a Q4 2024 submission of a Marketing Authorisation Application for its Grass MATA MPL immunotherapy after constructive discussions with the Paul Ehrlich Institut. The company’s pivotal G306 Phase III trial data and the planned inclusion of US patients in future studies align with its strategy to seek a Biologics License Application in the United States. CEO Manuel Llobet expresses optimism for the transformative potential of the vaccine for allergy sufferers worldwide.
For further insights into GB:AGY stock, check out TipRanks’ Stock Analysis page.
